Important: Tesamorelin is FDA-approved (as Egrifta) for one specific use and is otherwise sold for laboratory research only. It is not a weight-loss drug — its label is explicitly weight-neutral. This guide summarizes the research; it is not medical advice, and the doses below are study figures, not recommendations. Tesamorelin is prohibited by WADA at all times. Consult a licensed healthcare professional before using any research compound.
Most "GH peptides" are sold on mechanism and anecdote. Tesamorelin is different: it's the one growth-hormone-releasing peptide that ran the full gauntlet of randomized trials and earned FDA approval. But that approval is narrow and frequently misrepresented online — it's for reducing visceral fat, the deep abdominal fat around your organs, not for general weight loss. Understanding that distinction is the key to having realistic expectations.
| Quick facts | |
|---|---|
| What it is | Stabilized synthetic analog of GHRH (growth-hormone-releasing hormone) |
| Brand name | Egrifta / Egrifta SV / Egrifta WR |
| FDA-approved use | Reduce excess visceral abdominal fat in HIV-associated lipodystrophy |
| Mechanism | GHRH-receptor agonist → ↑ pulsatile GH → ↑ IGF-1 → visceral-fat lipolysis |
| Typical research dose | 2 mg subcutaneous, once daily |
| Effect on scale weight | Weight-neutral (it redistributes fat, not pounds) |
| Status | Rx drug (Egrifta); research-grade sold RUO; WADA-prohibited |
What tesamorelin is — and what it isn't#
Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH). Native GHRH is fragile and short-lived; tesamorelin's modified structure survives longer in the body while still binding the same pituitary receptor (Tesamorelin — NCBI LiverTox). It was approved by the FDA in 2010 under the brand Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy.
The single most important thing to get right: the FDA label states tesamorelin is for visceral fat reduction and is "not indicated for weight loss management," because it is weight-neutral (FDA Egrifta prescribing information). It changes where fat sits — shrinking the deep visceral fat around the organs — without moving the number on the scale much. If your goal is general weight loss, the GLP-1 peptides are the relevant class; see our best peptides for weight loss guide.
How tesamorelin works#
Tesamorelin activates GHRH receptors in the pituitary, prompting it to release growth hormone (GH) in the body's natural nocturnal pulses. That GH acts on the liver to raise IGF-1, and the combined GH/IGF-1 signal drives lipolysis — preferentially breaking down metabolically active visceral fat (NCBI LiverTox). Because it works upstream — stimulating your own GH rather than injecting GH directly — the pulsatile rhythm is preserved and IGF-1 feedback still limits runaway GH levels, which is part of why its side-effect profile is milder than exogenous HGH.
What the evidence shows: visceral fat and body composition#
This is where tesamorelin has genuine, peer-reviewed data — most of it in HIV-associated lipodystrophy, the population it was studied and approved in:
- Visceral fat reduction. In a randomized trial, 2 mg daily for 6 months significantly reduced visceral adipose tissue (mean change −34 cm² vs +8 cm² on placebo) and modestly lowered liver fat (Stanley et al., JAMA 2014). Across trials, tesamorelin reduces visceral fat on the order of 15–20% over 6–12 months (tesamorelin in HIV lipodystrophy review).
- Liver fat. Reductions in hepatic fat make it a subject of ongoing non-alcoholic fatty liver disease research.
- IGF-1 and lean mass. It reliably raises IGF-1 and supports lean body mass while cutting visceral fat — the "recomposition" appeal.
The honest boundary: this evidence is in people with HIV-associated lipodystrophy. Using tesamorelin for visceral fat in the general population is off-label and far less studied — the mechanism is the same, but you shouldn't assume the trial numbers transfer exactly.
Tesamorelin dosage and how it's used#
The studied and approved dose is 2 mg subcutaneously, once daily, typically injected into the abdomen and usually at night to align with natural GH pulses. It ships as a lyophilized powder that must be reconstituted with bacteriostatic water before measuring — and because the concentration depends on how much water you add, the syringe draw varies. Run your vial and target dose through our reconstitution calculator for the exact units, and see the step-by-step reconstitution guide for technique. As always, 2 mg/day is the trial figure, not a personal recommendation.
Tesamorelin before and after: a realistic results timeline#
"Before and after" searches expect dramatic transformation photos. The honest version is less cinematic but more useful — here's what the research actually supports over time:
| Timeframe | What the evidence supports |
|---|---|
| Weeks 1–2 | IGF-1 begins rising; possible mild injection-site reactions, fluid retention or joint aches as GH increases |
| Weeks 4–6 | Early visceral-fat mobilization begins; some report improved sleep and energy (anecdotal, not trial endpoints) |
| ~3 months | Measurable visceral fat reduction on imaging; the label advises reassessing if there's no VAT response by now |
| 6–12 months | Fuller visceral-fat reduction (~15–20% in trials), improved liver fat, preserved/improved lean mass — but scale weight is largely unchanged |
| After stopping | Visceral fat tends to re-accumulate — the benefit depends on continued use |
The two expectations to reset: it won't move the scale much (it's fat redistribution, not weight loss), and it isn't a muscle builder — for that, see our best peptides for muscle growth guide. The visible "before/after" is a slimmer waistline from losing deep abdominal fat, not a lower bodyweight.
Side effects and safety#
Tesamorelin is relatively well tolerated, but it has real, documented risks — and because it raises GH and IGF-1, some are mechanism-driven:
- Injection-site reactions — the most common; redness, itching, pain, bruising (about 25% vs 14% on placebo in trials).
- Joint and muscle aches, peripheral edema — fluid retention and arthralgia from increased GH.
- Increased diabetes/glucose risk — patients on Egrifta had a higher rate of developing diabetes than placebo (HbA1c ≥6.5%: 5% vs 1%) (FDA prescribing information). Glucose monitoring matters.
- Hypersensitivity reactions — occurred in ~4% of treated patients.
- Carpal-tunnel-type symptoms — numbness/tingling, again from fluid shifts.
Who should not use tesamorelin#
Per the FDA label and the drug's mechanism, tesamorelin is contraindicated or requires real caution in:
- Active malignancy — do not use; GH/IGF-1 stimulation can promote tumor growth. This is a material safety point, not a formality.
- Pituitary tumor, pituitary surgery, or head irradiation.
- Pregnancy.
- Diabetes or impaired glucose tolerance — use only with monitoring.
- Competitive athletes — tesamorelin is a GHRH analog explicitly named on the WADA Prohibited List and is banned at all times (USADA — peptide hormones).
Tesamorelin vs other GH peptides#
Tesamorelin sits among several growth-hormone peptides, and the differences are practical:
- vs [peptide:sermorelin]: both are GHRH analogs, but tesamorelin is more potent, longer-studied, and the only one FDA-approved — with specific visceral-fat data sermorelin lacks.
- vs [peptide:ipamorelin]: ipamorelin is a ghrelin-receptor agonist (a different GH trigger). It's often combined with tesamorelin (the "Tesamorelin + Ipamorelin" stack) to hit GH release through two pathways.
- vs [peptide:cjc-1295]: CJC-1295 is a longer-acting GHRH analog used more for general GH/IGF-1 elevation; tesamorelin is the choice when visceral fat is the specific target.
For where these fit in a muscle/recomp context, see our best peptides for muscle growth breakdown.
Where to buy tesamorelin#
Research-grade tesamorelin is sold by research-chemical suppliers for laboratory use only (the FDA-approved Egrifta is a separate, prescription product). Quality and price-per-mg vary, so a current COA matters. Peptide Supply Co. is our top-rated US source; compare live pricing below and see the full tesamorelin vendor comparison.
Frequently asked questions
What does tesamorelin do?
It stimulates your pituitary to release growth hormone in natural pulses, which raises IGF-1 and preferentially reduces visceral (deep abdominal) fat. It's FDA-approved for visceral fat in HIV-associated lipodystrophy and reliably raises IGF-1 and lean mass.
Is tesamorelin like Ozempic?
No. Ozempic (semaglutide) is a GLP-1 agonist that drives general weight loss by suppressing appetite. Tesamorelin is a GHRH analog that targets visceral fat specifically and is weight-neutral — it changes fat distribution, not bodyweight.
How long does tesamorelin take to work?
Visceral fat changes are typically measurable on imaging around 3 months, with fuller reductions over 6–12 months. IGF-1 rises within the first weeks. The FDA label suggests reassessing if there's no visceral-fat response by about 3 months.
How many times a week do you inject tesamorelin?
In trials it's dosed once daily (2 mg subcutaneously), not weekly — that's a key difference from the once-weekly GLP-1 peptides. This is the studied protocol, not a recommendation.
How much fat can you lose on tesamorelin?
Trials show roughly a 15–20% reduction in visceral adipose tissue over 6–12 months — but with little change in total bodyweight, because it targets deep abdominal fat rather than overall mass.
What happens when you stop tesamorelin?
Visceral fat tends to re-accumulate after stopping, so the benefit depends on continued use. This is one reason it's framed as an ongoing therapy rather than a short cycle.
Sources
- Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients — Randomized Clinical Trial. JAMA 2014 — PubMed
- Tesamorelin — LiverTox, NCBI Bookshelf (mechanism & safety)
- EGRIFTA (tesamorelin) — FDA Prescribing Information, DailyMed
- Spotlight on tesamorelin in HIV-associated lipodystrophy — review, PubMed
- USADA — 6 Things to Know About Peptide Hormones and Releasing Factors